Optune: Difference between revisions
(Created page with "{{TreatmentInfo |drug_name=Optune (Optune Gio® for newer version) |FDA_approval=Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications |used_for=Newly diagnosed glioblastoma, with trials for other cancers ongoing |clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing |common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, he...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 5: | Line 5: | ||
|clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing | |clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing | ||
|common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression | |common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression | ||
|OS_without=16 months (control group in EF-14 Trial) | |||
|OS_with=20.9 months (Optune plus temozolomide, final EF-14 analysis) | |OS_with=20.9 months (Optune plus temozolomide, final EF-14 analysis) | ||
|PFS_without=4 months (control group in EF-14 Trial) | |||
|PFS_with=7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis | |PFS_with=7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis | ||
|usefulness_rating=5 | |usefulness_rating=5 | ||
| Line 12: | Line 14: | ||
|book_text=Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients. | |book_text=Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients. | ||
|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments. | |notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments. | ||
| | |treatment_category=Innovative Cancer Therapies | ||
}} | }} | ||
Latest revision as of 10:38, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Optune (Optune Gio® for newer version) |
| FDA Approval | Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications |
| Used for | Newly diagnosed glioblastoma, with trials for other cancers ongoing |
| Clinical Trial Phase | Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression |
| OS without | 16 months (control group in EF-14 Trial) |
| OS with | 20.9 months (Optune plus temozolomide, final EF-14 analysis) |
| PFS without | 4 months (control group in EF-14 Trial) |
| PFS with | 7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis |
| Usefulness Rating | 5 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | Most common adverse reaction is skin irritation at the device contact points; no increase in systemic adverse events |
Notes: Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.
From Ben Williams Book: Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients.Property "Has original text" (as page type) with input value "Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
